id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2016-E-0533-0006,FDA,FDA-2016-E-0533,"Determination of Regulatory Review Period for Purposes of Patent
Extension; RAPIVAB",Notice,Determinations,2017-11-28T05:00:00Z,2017,11,2017-11-28T05:00:00Z,2018-01-30T04:59:59Z,2017-11-28T16:07:34Z,2017-25676,0,0,0900006482cb8369
FDA-2016-E-0533-0005,FDA,FDA-2016-E-0533,Letter from U.S. Patent and Trademark Office to CDER,Other,Letter(s),2017-07-24T04:00:00Z,2017,7,2017-07-24T04:00:00Z,,2017-07-24T20:56:24Z,,0,0,090000648295e070
FDA-2016-E-0533-0004,FDA,FDA-2016-E-0533,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2017-07-12T04:00:00Z,2017,7,2017-07-12T04:00:00Z,,2017-07-12T21:00:59Z,,0,0,09000064829145aa